In-Cell-Art, is a biopharmaceutical company specializing in the preclinical and pharmaceutical development of solution (DNA/RNA based vaccines or therapeutics) treating acquired or inherited diseases using patented bioinspired synthetic delivery systems (named Nanotaxi®) consisting of different chemical families (lipids, polymers).
Its founder and research team, which includes a Nobel Laureate, have developed this unique intellectual property expertise and know-how based on 20 years of research in the field of supramolecular nucleic acids transfection agents.
The vaccines and therapeutics developed by In-Cell-Art have been validated by numerous studies using infectious disease models (HIV, Flu, Dengue, dust mite, mycobacterium abscessus) , therapeutic cancer models (melanoma, liver, breast and cervical cancers) and therapeutic models (muscular dystrophy, anemia in kidney failure)
In-Cell-Art has recently advanced vaccines into regulatory preclinical studies for human clinical trials and shown promising safety and immunogenicity profiles.
In-Cell-Art’s people have international qualifications, experience and expertise in the fields of supramolecular chemistry, physico-chemical characterization and preclinical pharmaceutical development and include a highly experienced Scientific Advisory Board of recognized experts comprising Jean Marie Lehn (Nobel Laureate), Bruno Pitard, CSO of In-Cell-Art, Didier Roux, VP R&D of Saint Gobain, Luc Aujame former Senior Director in External R&D at Sanofi Pasteur and Georges-Bernard Guillou, MD, former director of Pharmaceutical R&D and Scientific Affairs & Licensing at Laboratoires Expanscience.
In-Cell-Art is based in Nantes (France) and member of Atlanpole Biotherapies cluster of biotechnology companies focusing in the development of biotherapeutics.
